GlassScriptPhysician profile
Lori Kleiman
NPI 1942403332
$1,846.89
in general payments reported to CMS, 2019-2025
37 companies · $747 in 2025
The $747 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $162 · 2022: $289 · 2023: $282 · 2024: $366 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,395.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $233.72 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurelis, INC. | $165.05 | 2023-2025 | Valtoco |
| Ucb, INC. | $126.64 | 2021-2025 | Fintepla, Nayzilam, Zilbrysq |
| Biogen, INC. | $97.29 | 2021-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $88.54 | 2023-2025 | Kisunla, Amyvid, Reyvow |
| Janssen Pharmaceuticals, INC | $81.64 | 2022 | |
| Tg Therapeutics, INC. | $69.88 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $67.28 | 2022-2024 | Ingrezza |
| Argenx US, INC. | $62.14 | 2023-2025 | Vyvgart Hytrulo |
| Lundbeck LLC | $60.14 | 2025 | Vyepti |
| Abbvie INC. | $53.80 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $53.45 | 2023-2025 | Rexulti |
| Saluda Medical Americas, INC. | $50.32 | 2025 | Evoke |
| Biohaven Pharmaceuticals, INC. | $45.92 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.10 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $39.57 | 2025 | Belbuca |
| Nevro Corp. | $38.58 | 2022-2024 | Senza |
| Sk Life Science, INC. | $37.91 | 2024-2025 | |
| Pfizer INC. | $36.09 | 2025 | |
| Jazz Pharmaceuticals INC. | $31.97 | 2024 | |
| Amgen INC. | $31.47 | 2021-2023 | Aimovig |
| Genentech USA, INC. | $29.69 | 2024 | Ocrevus Zunovo |
| Amneal Pharmaceuticals LLC | $27.30 | 2025 | Ongentys |
| Alexion Pharmaceuticals, INC. | $26.99 | 2025 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $26.91 | 2025 | Onpattro |
| Appliedvr INC | $23.47 | 2025 | Relievrx |
| Eisai INC. | $23.44 | 2023 | |
| Merz Pharmaceuticals, LLC | $23.05 | 2025 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $21.93 | 2025 | Wainua |
| Grifols USA, LLC | $21.32 | 2025 | Gamunex-C |
| Scilex Pharmaceuticals INC. | $18.47 | 2022 | |
| Axsome Therapeutics, INC. | $17.13 | 2025 | Symbravo |
| W. L. Gore & Associates, INC. | $16.72 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $15.84 | 2025 | |
| Avanir Pharmaceuticals, INC. | $15.41 | 2021 | |
| Boston Scientific Corporation | $14.58 | 2021 | |
| Protega Pharmaceutials INC | $12.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lori Kleiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.